Gilotrif (afatinib; formerly Tomtovok) for First-Line Treatment of Lung Cancer

An oral second-generation tyrosine kinase inhibitor for first-line treatment of metastatic non-small cell lung cancer.

If you have a Hayes login, click here to view the full report on the Knowledge Center.